CNA938 Rewind - Ozempic goes generic: A game-changer for global healthcare?

A major shift in the pharmaceutical world – the patent behind Ozempic’s key ingredient has expired across major markets, opening the floodgates for cheaper, mass-produced versions of the blockbuster drug. Andrea Heng and Hairianto Diman explore how countries like India and China are already gearing up to roll out low-cost generics at scale, potentially slashing prices by more than half and expanding access to millions and what this means for the future of weight-loss and diabetes treatment. To find out more, they speak with Evan Seigerman, Head of Healthcare Research focusing on BioPharma and Biotechnology, BMO Capital Markets.